E7F0.F CIZZLE BIOTECHN. LS-0001

Healthcare Biotechnology Frankfurt Exchange
0.0130 EUR
Close of Nov 11, 2026
0.0100 0.0395
Market cap
EUR 6.24M
P/E
-
P/B
4.76x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is E7F0.F undervalued?

Graham number

The Graham number of CIZZLE BIOTECHN. LS-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CIZZLE BIOTECHN. LS-0001 fundamental analysis

No fundamental analysis for CIZZLE BIOTECHN. LS-0001 yet.

CIZZLE BIOTECHN. LS-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CIZZLE BIOTECHN. LS-0001

Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood immunoassay test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.

Full company profile